MRX11 Antibody

What is MRP1 and why are antibodies against it important in research?

MRP1, also known as ABCC1 (ATP-binding cassette sub-family C member 1), functions as a crucial membrane transport protein that mediates the export of organic anions and drugs from the cytoplasm. MRP1 mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs, and various xenobiotics . Antibodies against MRP1 have become essential research tools because they enable scientists to study mechanisms of multidrug resistance in cancer cells, investigate cellular detoxification processes, and examine the role of MRP1 in inflammatory responses. Additionally, MRP1 has been shown to catalyze the export of sphingosine 1-phosphate from mast cells and participates in inflammatory responses by facilitating leukotriene C4 export .

How do I select the appropriate MRP1 antibody for my research?

When selecting an MRP1 antibody for your research, consider the following methodological approach:

• Determine required cross-reactivity: Identify whether you need an antibody that recognizes only human MRP1 or one that also recognizes rodent MRP1. Polyclonal antibodies like MRP1-A23 allow detection of both human and rodent MRP1, making them valuable for translational research comparing human and animal models .

• Evaluate application compatibility: Match the antibody to your intended application. For example, the mouse monoclonal MRP1 antibody MRPm5 is suitable for multiple applications including Western blot (WB), immunohistochemistry (IHC-P, IHC-Fr), immunocytochemistry/immunofluorescence (ICC/IF), and flow cytometry .

• Consider the targeted epitope: The epitope recognition pattern is critical for antibody functionality. MRP1-A23, for instance, was produced against a synthetic polypeptide covering the C-terminus of the human protein, while MRPm5 recognizes a recombinant fragment within human ABCC1 amino acids 950-1250 .

• Review validation evidence: Examine literature citations and validation data supporting the antibody's specificity. MRPm5 has been cited in 59 publications, suggesting substantial validation across multiple research contexts .

What controls should I include when using MRP1 antibodies in my experiments?

A comprehensive control strategy is essential when using MRP1 antibodies:

• Positive controls: Include cell lines or tissues known to express MRP1 (e.g., drug-resistant cancer cell lines). This validates that your antibody can detect the target when present.

• Negative controls: Incorporate samples with no or minimal MRP1 expression, or use MRP1 knockout models when available.

• Cross-reactivity controls: If working with human and rodent samples, test for potential cross-reactivity with related proteins. For example, MRP1-A23 shows no cross-reactivity with human or mouse MRP2 but weakly cross-reacts with rat MRP2 in the protein region ranging from 1512 to 1533 amino acids .

• Peptide competition: Use the immunizing peptide to block antibody binding, confirming specificity of detection.

• Secondary antibody controls: Include samples treated only with secondary antibody to identify non-specific binding.

For Western blot experiments specifically, include molecular weight markers to confirm that the detected band corresponds to the expected MRP1 size, as this provides additional validation of antibody specificity .

How can I effectively use MRP1 antibodies to study drug resistance mechanisms in cancer?

To effectively study drug resistance mechanisms using MRP1 antibodies, implement the following methodological approach:

• Correlative expression studies: Quantify MRP1 expression levels across drug-sensitive and drug-resistant cancer cell populations using calibrated Western blot or flow cytometry with MRP1 antibodies. This allows correlation between expression levels and drug resistance phenotypes.

• Functional inhibition experiments: Combine antibody detection of MRP1 with functional assays measuring drug accumulation in cells. This establishes the causal relationship between MRP1 expression and decreased drug accumulation, a hallmark of its resistance mechanism .

• Mechanistic investigations: Use MRP1 antibodies in co-immunoprecipitation experiments to identify protein interaction partners involved in the ATP- and GSH-dependent drug export functions .

• Subcellular localization studies: Employ immunofluorescence with MRP1 antibodies to track changes in protein localization during acquisition of drug resistance, providing insights into trafficking mechanisms.

• Translational research: Apply validated antibodies like MRP1-A23 across human samples and rodent models to establish clinically relevant mechanisms that span species boundaries .

The selection of specific antibodies for these applications should consider epitope accessibility in different experimental contexts and potential interference with MRP1 function.

What are the considerations for using MRP1 antibodies in combination with other antibodies for multiplex detection?

Implementing multiplex detection systems with MRP1 antibodies requires careful methodological planning:

• Antibody source species differentiation: When combining multiple primary antibodies, select those raised in different host species (e.g., mouse anti-MRP1 with rabbit anti-target2) to enable detection with species-specific secondary antibodies.

• Isotype selection: If using multiple antibodies from the same species, differentiate by selecting antibodies of distinct isotypes and use isotype-specific secondary antibodies.

• Fluorophore compatibility: For immunofluorescence multiplex detection, select fluorophores with minimal spectral overlap to avoid bleed-through. Consider sequential staining protocols if antibody cross-reactivity is a concern.

• Epitope accessibility verification: Confirm that fixation and permeabilization methods preserve all target epitopes simultaneously. Different proteins may require optimized fixation protocols.

• Antibody blocking strategy: Implement complete blocking between sequential detection steps when using antibodies from the same species to prevent cross-reactivity.

For example, when studying MRP1's role in inflammatory responses, you might combine MRP1 antibodies with antibodies against inflammatory mediators to simultaneously visualize their spatial relationship in tissues or cells .

How can I use MRP1 antibodies to investigate the relationship between MRP1 and the cGAS-STING pathway?

Recent research has identified MRP1 as a regulator of the cGAS-STING pathway through its ATP-dependent, GSH-independent cyclic GMP-AMP (cGAMP) export function. To investigate this relationship using MRP1 antibodies:

• Protein quantification studies: Use Western blot with MRP1 antibodies to quantify MRP1 expression levels in cells with altered cGAS-STING pathway activity.

• Proximity ligation assays: Combine MRP1 antibodies with antibodies against cGAS or STING components to visualize and quantify protein proximity in situ.

• Immunoprecipitation approaches: Use MRP1 antibodies to pull down protein complexes, followed by detection of cGAS-STING pathway components to identify physical interactions.

• Transport activity correlation: Correlate MRP1 expression levels (detected by antibodies) with measurements of intracellular cGAMP concentrations to establish functional relationships.

• Genetic manipulation validation: Confirm antibody specificity in MRP1 knockdown or knockout systems while monitoring cGAS-STING pathway activity markers.

This methodology allows researchers to elucidate how MRP1 contributes to immune regulation by limiting intracellular cGAMP concentrations and negatively regulating the cGAS-STING pathway .

What are the optimal protocols for using MRP1 antibodies in Western blot applications?

For optimal Western blot detection of MRP1 using antibodies, follow this detailed protocol:

• Sample preparation:

  • Extract proteins using buffers containing appropriate detergents (e.g., 1% Triton X-100) to solubilize membrane-bound MRP1

  • Add protease inhibitors to prevent degradation

  • Avoid excessive heating during sample preparation as it may cause aggregation of membrane proteins

• Protein separation:

  • Use 7-8% SDS-PAGE gels to properly resolve the high molecular weight MRP1 (approximately 190 kDa)

  • Load sufficient protein (25-50 μg of total protein per lane) to ensure detection

  • Include molecular weight markers spanning the 150-250 kDa range

• Protein transfer:

  • Implement wet transfer at lower voltage (30V) overnight at 4°C for efficient transfer of large proteins

  • Use PVDF membranes with 0.45 μm pore size rather than 0.2 μm for better binding of large proteins

• Antibody incubation:

  • Block membranes with 5% non-fat dry milk or BSA in TBST for 1 hour

  • Dilute primary MRP1 antibodies according to manufacturer recommendations (typically 1:500 to 1:1000)

  • Incubate with primary antibody overnight at 4°C with gentle agitation

  • Use appropriate HRP-conjugated secondary antibodies (typically 1:5000 dilution)

• Detection optimization:

  • Employ enhanced chemiluminescence with longer exposure times if necessary

  • Consider using signal enhancers for low abundance detection

This protocol has been validated with antibodies like MRP1-A23, which shows reactivity against human MRP1 similar to that obtained with the monoclonal QCRL1 antibody .

How should I optimize immunohistochemistry protocols for MRP1 antibody detection in tissue samples?

Optimizing immunohistochemistry (IHC) protocols for MRP1 detection requires systematic attention to several methodological parameters:

• Tissue preparation and fixation:

  • For formalin-fixed paraffin-embedded (FFPE) tissues, limit fixation time to 24 hours to preserve epitope integrity

  • Consider using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) for antigen retrieval

  • For frozen sections, use acetone or methanol fixation (10 minutes at -20°C) to maintain membrane protein conformation

• Blocking and permeabilization:

  • Block with 5-10% normal serum from the same species as the secondary antibody

  • Include 0.1-0.3% Triton X-100 for permeabilization to access intracellular epitopes

  • Consider including avidin/biotin blocking if using biotin-based detection systems

• Antibody selection and dilution:

  • Test a range of antibody dilutions (starting from 1:100 to 1:1000)

  • Mouse monoclonal MRP1 antibodies like MRPm5 have been validated for IHC-P and IHC-Fr applications

  • Incubate primary antibody overnight at 4°C in a humidified chamber

• Detection system optimization:

  • For low expression detection, use polymer-based detection systems or tyramide signal amplification

  • Include proper controls on each slide (positive and negative tissue controls)

  • Consider dual immunofluorescence with cell type-specific markers for co-localization studies

• Counterstaining and imaging:

  • Use minimal hematoxylin counterstaining to avoid masking specific staining

  • Employ spectral imaging for tissues with high autofluorescence when using fluorescent detection

This optimized approach ensures specific detection of MRP1 in complex tissue environments while minimizing background and non-specific binding issues.

What techniques should I use to validate the specificity of MRP1 antibody detection in my experimental system?

A comprehensive validation strategy for MRP1 antibodies should include multiple complementary approaches:

• Genetic validation:

  • Compare antibody signal in wild-type versus MRP1 knockout/knockdown systems

  • Use siRNA/shRNA to create a gradient of expression levels for correlation analysis

  • Employ CRISPR-Cas9 editing to generate epitope-modified MRP1 to confirm binding specificity

• Peptide competition assays:

  • Pre-incubate the antibody with excess immunizing peptide prior to application

  • Compare signal with and without peptide competition to identify specific binding

  • Include gradient concentrations of competing peptide to demonstrate dose-dependent inhibition

• Multi-antibody validation:

  • Compare detection patterns using antibodies targeting different epitopes of MRP1

  • Confirm consistent expression patterns across multiple antibodies like MRP1-A23 and MRPm5

• Cross-species reactivity testing:

  • Test antibody performance across human, mouse, and rat samples if working with multiple species

  • MRP1-A23 has demonstrated specificity for MRP1 across these species with minimal cross-reactivity to MRP2

• Correlation with functional assays:

  • Correlate antibody-detected expression levels with functional measurements of MRP1 activity

  • Measure drug export capabilities in cells with variable MRP1 expression levels

• Mass spectrometry validation:

  • Perform immunoprecipitation with the MRP1 antibody followed by mass spectrometry to confirm target identity

This multi-faceted approach significantly reduces the risk of misinterpreting results due to antibody cross-reactivity or non-specific binding.

How can I address weak or absent signal when using MRP1 antibodies in Western blot analysis?

When encountering weak or absent MRP1 signal in Western blot analysis, implement this systematic troubleshooting approach:

• Sample preparation optimization:

  • Ensure adequate protein extraction by using stronger lysis buffers (containing SDS or deoxycholate) for membrane proteins

  • Avoid repeated freeze-thaw cycles of samples which may degrade membrane proteins

  • Confirm protein concentration using reliable assays that are compatible with detergents

• Technical adjustments:

  • Increase protein loading (50-100 μg total protein per lane)

  • Extend primary antibody incubation time to overnight at 4°C

  • Decrease antibody dilution (use more concentrated antibody)

  • Extend exposure time during detection

  • Use more sensitive detection systems (enhanced ECL or fluorescent secondary antibodies)

• MRP1 expression considerations:

  • Verify MRP1 expression in your samples with RT-PCR before protein analysis

  • Use positive control samples with known MRP1 expression (drug-resistant cell lines)

  • Consider that MRP1 expression may be induced by certain conditions like oxidative stress

• Antibody selection refinement:

  • Try alternative MRP1 antibodies targeting different epitopes

  • Polyclonal antibodies like MRP1-A23 may provide better sensitivity for detecting low-abundance MRP1

  • Consider that certain epitopes may be masked by protein interactions or post-translational modifications

• Buffer and blocking optimization:

  • Test alternative blocking agents (BSA instead of milk for phospho-specific antibodies)

  • Reduce washing stringency by decreasing detergent concentration in wash buffers

This methodical approach helps distinguish between technical issues and true biological absence of MRP1 expression.

What are common sources of background or non-specific binding when using MRP1 antibodies, and how can they be minimized?

Several factors can contribute to background or non-specific binding with MRP1 antibodies. Here's how to address them:

• Inadequate blocking:

  • Extend blocking time to 2 hours at room temperature

  • Increase blocking agent concentration to 5-10%

  • Add 0.1-0.3% Triton X-100 or Tween-20 to blocking buffer to reduce hydrophobic interactions

  • Consider alternative blocking agents (casein, fish gelatin) if milk or BSA gives high background

• Secondary antibody cross-reactivity:

  • Use highly cross-adsorbed secondary antibodies

  • Include 1-5% serum from the host species of your samples in antibody dilution buffer

  • Run a control omitting primary antibody to identify secondary antibody issues

• Fixation artifacts:

  • Optimize fixation protocols to preserve epitope structure while maintaining tissue morphology

  • Ensure complete deparaffinization of FFPE samples

  • Optimize antigen retrieval conditions (pH, temperature, duration)

• Tissue-specific considerations:

  • For tissues with high endogenous peroxidase activity (liver, kidney), enhance peroxidase quenching steps

  • For tissues with high endogenous biotin (liver, kidney), implement avidin-biotin blocking

  • Use Sudan Black B (0.1-0.3%) to reduce autofluorescence in immunofluorescence applications

• Antibody specificity issues:

  • Test for potential cross-reactivity with related proteins like MRP2, particularly when using polyclonal antibodies like MRP1-A23 which may show weak cross-reactivity with rat MRP2

  • Implement peptide competition controls to distinguish specific from non-specific binding

  • Consider targeted validation in confounding tissues with known expression profiles

Systematically addressing these factors will significantly improve signal-to-noise ratio and data reliability in MRP1 detection experiments.

How should I quantify and normalize MRP1 expression data from Western blot or immunohistochemistry experiments?

Accurate quantification and normalization of MRP1 expression requires rigorous methodological approaches:

For Western blot quantification:

• Signal detection optimization:

  • Ensure detection is in the linear range of your imaging system

  • Avoid saturated pixels which compromise quantitative analysis

  • Capture multiple exposure times to identify optimal quantification range

• Densitometry approaches:

  • Use integrated density measurements rather than peak intensity

  • Subtract local background from each lane individually

  • Analyze triplicate biological samples for statistical validity

• Normalization strategies:

  • Normalize to multiple housekeeping proteins (e.g., β-actin, GAPDH, α-tubulin)

  • Consider membrane protein-specific loading controls (Na⁺/K⁺-ATPase)

  • Use total protein normalization methods (Ponceau S, SYPRO Ruby, stain-free technology) to overcome limitations of single housekeeping proteins

For immunohistochemistry quantification:

• Digital image analysis:

  • Use calibrated image acquisition settings across all samples

  • Employ color deconvolution algorithms to separate specific staining from counterstains

  • Implement machine learning-based segmentation for cell-type specific quantification

• Scoring methodologies:

  • Develop clearly defined scoring systems (0-3+ intensity scale)

  • Calculate H-scores (∑(intensity × percentage of positive cells))

  • Have multiple independent observers score samples blindly

• Reference standards:

  • Include internal reference controls in each experiment

  • Use tissue microarrays containing gradients of MRP1 expression for standardization

  • Consider automated, algorithm-based quantification to reduce observer bias

• Statistical analysis:

  • Use appropriate statistical tests based on data distribution

  • Account for multiple comparisons when analyzing large datasets

  • Report confidence intervals alongside point estimates

This comprehensive approach to quantification enhances reproducibility and reliability of MRP1 expression analysis across experimental systems.

How are MRP1 antibodies being utilized in the development of antibody-drug conjugates (ADCs) for cancer therapy?

Recent advances in antibody therapeutics have expanded the application of MRP1-targeting antibodies in the development of antibody-drug conjugates:

• Target validation strategies:

  • MRP1 antibodies are used to validate differential expression between normal and cancer tissues, establishing MRP1 as a potential ADC target

  • Quantitative immunohistochemistry with validated MRP1 antibodies helps determine tumor type suitability for MRP1-targeted ADCs

  • Flow cytometry with MRP1 antibodies enables precise quantification of cell surface exposure needed for ADC engagement

• ADC development methodology:

  • Internalization studies tracking fluorescently-labeled MRP1 antibodies help assess their suitability as ADC delivery vehicles

  • Antibodies recognizing extracellular epitopes of MRP1 are evaluated for their ability to deliver cytotoxic payloads

  • Competition assays determine whether antibodies interfere with MRP1's drug efflux function, potentially enhancing ADC efficacy

• Dual-function approaches:

  • Research explores antibodies that both inhibit MRP1 drug efflux function and deliver cytotoxic payloads

  • MRP1 antibodies conjugated to payloads that become substrates for other ABC transporters create multi-targeting strategies

  • Bispecific antibody derivatives targeting both MRP1 and other cancer markers enhance specificity

• Resistance mechanism insights:

  • MRP1 antibodies help identify potential resistance mechanisms to other ADCs, as several ADC payloads are MRP1 substrates

  • Understanding gained from antibody-based studies of MRP1 informs the development of newer ADCs like datopotamab deruxtecan and patritumab deruxtecan currently in regulatory review

This integration of MRP1 antibody research with ADC development represents a promising frontier in overcoming multidrug resistance in cancer therapy.

What role do antibodies play in understanding the impact of MRP1 on the cGAS-STING pathway in immunity and cancer?

Antibodies are instrumental in elucidating the newly discovered relationship between MRP1 and the cGAS-STING pathway:

• Mechanistic investigation approaches:

  • Co-immunoprecipitation experiments using MRP1 antibodies help identify protein-protein interactions within the cGAS-STING pathway

  • Immunofluorescence co-localization studies with MRP1 and STING component antibodies reveal spatial relationships during pathway activation

  • Western blot analysis quantifies how modulating MRP1 affects the expression of downstream STING pathway components

• Functional correlation methodologies:

  • Flow cytometry with MRP1 antibodies correlates surface expression levels with intracellular cGAMP concentrations

  • ChIP sequencing with antibodies against transcription factors activated by the STING pathway helps determine genes regulated following MRP1-mediated cGAMP export

  • Proximity ligation assays using antibody pairs detect molecular interactions between MRP1 and STING pathway components

• Translational research applications:

  • Tissue microarray analysis with MRP1 antibodies across cancer types helps identify correlations between MRP1 expression and immune infiltration

  • Single-cell analysis combining MRP1 antibodies with immune markers reveals cell population-specific effects

  • Patient-derived xenograft models analyzed with human-specific MRP1 antibodies like MRPm5 enable in vivo validation of pathway relationships

• Therapeutic development insights:

  • Antibody-based screening identifies compounds that modulate MRP1's cGAMP transport without affecting other substrates

  • Competition binding assays with MRP1 antibodies help characterize novel inhibitors targeting the cGAMP export function

  • Immune checkpoint combination studies utilize MRP1 antibodies to track expression changes during treatment

These antibody-dependent approaches are revealing how MRP1-mediated regulation of the cGAS-STING pathway influences both immunity and cancer progression, potentially opening new therapeutic avenues .

How can researchers integrate MRP1 antibody-based detection with other molecular techniques for comprehensive drug resistance profiling?

An integrated approach combining MRP1 antibody detection with complementary molecular techniques enables comprehensive drug resistance profiling:

• Multi-omics integration strategies:

  • Correlate MRP1 protein levels (detected by antibodies) with mRNA expression (measured by RT-qPCR or RNA-seq)

  • Combine MRP1 antibody-based protein quantification with metabolomic profiling of MRP1 substrates

  • Integrate chromatin immunoprecipitation data on MRP1 gene regulation with protein expression patterns

• Functional assay correlation:

  • Pair MRP1 antibody detection with fluorescent substrate accumulation assays to link expression and transport activity

  • Combine immunofluorescence localization of MRP1 with live-cell imaging of drug efflux kinetics

  • Correlate MRP1 expression with IC50 values for various therapeutics to establish quantitative resistance relationships

• Single-cell analysis approaches:

  • Implement mass cytometry (CyTOF) with MRP1 antibodies alongside drug resistance markers for high-dimensional profiling

  • Use imaging mass cytometry to maintain spatial context while quantifying MRP1 and related proteins

  • Apply single-cell RNA-seq with antibody-based cell sorting to correlate transcriptomes with MRP1 protein levels

• Clinical sample workflows:

  • Develop standardized protocols combining MRP1 immunohistochemistry with genetic testing for other resistance mechanisms

  • Implement liquid biopsy workflows that capture both circulating tumor cells (analyzed with MRP1 antibodies) and cell-free DNA

  • Create patient-derived organoid platforms with integrated MRP1 antibody-based monitoring of drug resistance evolution

• Mathematical modeling approaches:

  • Develop predictive algorithms incorporating MRP1 expression data from antibody-based detection with drug response profiles

  • Build network models integrating MRP1 with other ABC transporters and resistance mechanisms

  • Create patient-specific resistance profiles based on integrated antibody and molecular data

This integrated approach provides a more comprehensive understanding of the multifactorial nature of drug resistance than any single technique alone, potentially enabling more effective personalized treatment strategies.